Bristol-Myers Squibb Co. (BMY) said that the European Commission or EC has approved Opdivo, or nivolumab, for the adjuvant treatment of adult patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection. This indication is for both BRAF mutant and wild-type melanoma patients.
from RTT - Biotech https://ift.tt/2mUGVBc
via IFTTT
No comments:
Post a Comment